Peptide therapy for bodybuilding: separating gym hype from real data

What did @kodi_dyel actually say?

The creator reviewed a ranked list of anabolic and performance compounds ordered from least to most dangerous. He broadly agreed with the original ranking but pushed back on a few placements. His most specific technical claim: NPP and Deca (nandrolone esters) are "seven or eight times more blood vessel toxic than regular testosterone." He also called Anadrol "gyno in a bottle," flagged EQ for blood thickening, dismissed MENT as underrated in toxicity, and kept DNP, insulin, and EPO at the bottom of the risk ladder, meaning highest danger. He rated Halotestin as maximally dangerous due to "neurotoxicity, liver toxicity" and its psychological effects. Peptides and TRT sat at the top of his list as lowest risk. He acknowledged he agreed with roughly 60% of the original ranking.

Does the science back this up?

Partially. Some of his instincts are defensible. Others rely on gym-floor folklore dressed up as clinical reasoning. The nandrolone cardiovascular claim is the most verifiable, and it holds up better than you might expect, though the exact multiplier he cites is fuzzy. His Halotestin neurotoxicity concern is real but underexplained. His dismissal of MENT is worth taking seriously.

On nandrolone cardiovascular risk: research does show nandrolone has outsized negative effects on lipid profiles and vascular endothelial function compared to testosterone at equivalent doses. Ritter et al. (2017, Toxicology Letters) and Baggish et al. (2017, Circulation) both documented disproportionate left ventricular dysfunction and dyslipidemia in nandrolone users. The "seven or eight times" figure is not a clean number from any single study, but directionally, nandrolone's cardiovascular burden is meaningfully worse than testosterone's at comparable doses. That part checks out in spirit.

On Halotestin (fluoxymesterone): the hepatotoxicity is well-documented. The neurobehavioral effects, aggression, mood instability, are linked to its high androgenic activity. Shahidi (2001, Clinical Journal of Sport Medicine) reviewed fluoxymesterone and noted its extreme androgenic-to-anabolic ratio drives both liver stress and psychiatric risk. His instinct to keep it at maximum danger is reasonable.

What did they get wrong (or right)?

He got the broad strokes right on several compounds. Peptides genuinely carry a lower acute risk profile than supraphysiologic androgens. That is not controversial. Insulin at the bottom as highest risk is also correct: hypoglycemia from exogenous insulin misuse has killed bodybuilders, and this is not hyperbole.

Where he gets sloppy: calling Anadrol (oxymetholone) "gyno in a bottle" implies it aromatizes heavily. It does not aromatize in the traditional sense. Its estrogenic activity is thought to come from direct agonism at the estrogen receptor, not conversion to estradiol. That distinction matters clinically. Llewellyn (Anabolics, 2011) and Persky et al. (2003, Hepatology) both note that standard aromatase inhibitors are often ineffective against oxymetholone-induced gynecomastia for exactly this reason. So his warning is directionally right, his mechanism is wrong, and that gap could mislead someone into thinking an AI will solve the problem.

His EQ blood viscosity concern is legitimate. Equipoise (boldenone undecylenate) is well-known to elevate hematocrit and erythropoietin levels. Tailor et al. (2020, Drug Testing and Analysis) confirmed erythropoietic effects. His skepticism is earned here.

What should you actually know?

Risk rankings like this make for engaging content but are inherently incomplete. Dose, duration, individual genetics, stacking combinations, and health history all change the equation dramatically. A compound that sits "low risk" on a list can become genuinely dangerous depending on context.

A few things worth being clear about. DNP (2,4-dinitrophenol) is not a gray area. It has no therapeutic index. Multiple fatalities have been reported in the UK and US from single-dose exposures. Petróczi et al. (2015, BMC Pharmacology and Toxicology) documented multiple UK deaths in young adults. It does not belong in any risk conversation framed as "manageable."

EPO misuse carries stroke and thrombosis risk, especially during sleep when heart rate drops. Lundby et al. (2008, British Journal of Pharmacology) documented hematocrit-driven mortality risk in endurance athletes. The creator was right to flag it but did not explain why.

Peptides are not a monolith. BPC-157, TB-500, and related compounds are not FDA-approved. Research is mostly preclinical or early-phase. Calling them universally low-risk glosses over a real lack of long-term human safety data.

Bottom line

This video is more credible than most content in this category. The creator shows genuine familiarity with the compounds and pushes back with some evidence-adjacent reasoning. But it is still one person's opinion presented without citations, and at least one mechanistic claim (Anadrol aromatization) is outright wrong in a way that could matter to someone making decisions. If you are evaluating any of these compounds for any purpose, this video is a starting point for curiosity, not a substitute for clinical evaluation.